Biomea - BMEA Quarterly EPS earnings growth

Biomea Fusion Corp - graphic logo of issuer BMEA

Market expectations are focused on Thomas Butler's team, whose leadership during clinical trials is driving volatile interest. On GURU.Markets, the intensity of quarterly EPS growth demonstrates the asset's resilience, where the current parameter equals 68.30. Stability is maintained through production outsourcing to CDMO plants, while the uniqueness of covalent inhibitors for combating diabetes guarantees Biomea Fusion, Inc. (BMEA) dominant pricing power.

Biomea Fusion (BMEA) - Year-over-year earnings per share growth for the last twelve months from 07/04/2022 to 11/15/2026

Financial and market metric breakdowns for Biomea Fusion, Inc. (BMEA)

- share price and consensus valuation forecast:
Stock Quotes Biomea Fusion|BMEA - Analyst Forecast Prices
- issuer market value details:
Market Capitalization Biomea Fusion Corp|BMEA - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Biomea Fusion|BMEA - Company Book Value|Market Value to Book Value Ratio biomeafusion.com|BMEA - Company Assets
- debt and liquidity data:
Debt to Equity Biomea Fusion, Inc.|BMEA - Long-Term Debt to Equity|Short-Term Debt to Capital Biomea Fusion Inc|BMEA - Company Total Debt Obligations|Debt to Book Capitalization Ratio Biomea Fusion Inc|BMEA - Long-Term Debt Volume|Company Short-Term Debt Biomea Fusion|Quick Ratio biomeafusion.com
- earnings and valuation multiples indicators:
BMEA - Company Net Income|Projected Future Earnings Biomea Fusion, Inc.|BMEA - Business Payback Period|Future Price to Earnings Biomea Fusion Inc|BMEA - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biomea Fusion, Inc.|BMEA - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Biomea Fusion|BMEA - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth biomeafusion.com|BMEA - Earnings growth in current year|Expected earnings per share growth for next year Biomea Fusion, Inc.
- sales volume and revenue information:
BMEA - Company Sales Revenue|Projected Sales Volume Biomea Fusion|BMEA - Price-to-Sales Ratio|Forward Price-to-Revenue Multiple Biomea Fusion Corp|BMEA - Sales Growth YoY (TTM)
Analysis of all company metrics:Biomea Fusion, Inc.
Manufactured product of Biomea Fusion Corp

Quarterly EPS growth measures the dynamics of net income per share, excluding random market fluctuations. By analyzing the recorded quarterly EPS growth, an investor assesses the real efficiency of capital generation. This metric calculates the percentage deviation of the current result from the previous period to determine the profitability trend. For Biomea Fusion, Inc. (BMEA), this indicator reflects financial stability during the development of innovative diabetes drugs. Positive momentum here confirms the commercial potential of advanced covalent molecules.

Competitors of Biomea Fusion, Inc. (BMEA)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (Metsera, Inc.)|Year-over-year earnings per share growth for the last twelve months moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|FOLD: Quarterly EPS earnings growth|ETNB - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Agios Corp|Structure Corp (GPCR) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months mimedx.com (MDXG)|Year-over-year net earnings per share growth for the last 12 months rezolutebio.com RZLT|Year-over-year earnings per share growth for the last twelve months Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Year-over-year earnings per share growth for the last twelve months|ALT: Year-over-year net earnings per share growth for the last 12 months|AARD - Quarterly EPS earnings growth|SGMT: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months BioAge Labs, Inc. (BIOA)|Year-over-year earnings per share growth for the last twelve months Quince Therapeutics, Inc.|Year-over-year net earnings per share growth for the last 12 months Fractyl (GUTS)|Year-over-year net earnings per share growth for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Earnings per share growth in annualized terms for the last twelve months|Pluri Inc. - Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Synlogic Corp|LPCN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma Holdings, Inc. MTNB|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS